GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (NAS:SCTL) » Definitions » EV-to-Revenue

Societal CDMO (Societal CDMO) EV-to-Revenue : 1.65 (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Societal CDMO EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Societal CDMO's enterprise value is $155.86 Mil. Societal CDMO's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $94.64 Mil. Therefore, Societal CDMO's EV-to-Revenue for today is 1.65.

The historical rank and industry rank for Societal CDMO's EV-to-Revenue or its related term are showing as below:

SCTL' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.65   Med: 1.93   Max: 8.04
Current: 1.65

During the past 13 years, the highest EV-to-Revenue of Societal CDMO was 8.04. The lowest was 0.65. And the median was 1.93.

SCTL's EV-to-Revenue is ranked better than
64.07% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs SCTL: 1.65

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Societal CDMO's stock price is $1.10. Societal CDMO's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.00. Therefore, Societal CDMO's PS Ratio for today is 1.10.


Societal CDMO EV-to-Revenue Historical Data

The historical data trend for Societal CDMO's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Societal CDMO EV-to-Revenue Chart

Societal CDMO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.23 2.52 2.10 1.77 0.75

Societal CDMO Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 1.58 1.55 0.92 0.75

Competitive Comparison of Societal CDMO's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Societal CDMO's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Societal CDMO's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societal CDMO's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Societal CDMO's EV-to-Revenue falls into.



Societal CDMO EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Societal CDMO's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=155.864/94.635
=1.65

Societal CDMO's current Enterprise Value is $155.86 Mil.
Societal CDMO's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $94.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Societal CDMO  (NAS:SCTL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Societal CDMO's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.10/1.002
=1.10

Societal CDMO's share price for today is $1.10.
Societal CDMO's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Societal CDMO EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Societal CDMO's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Societal CDMO (Societal CDMO) Business Description

Traded in Other Exchanges
N/A
Address
1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341
Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.
Executives
Bryan M. Reasons director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Elena Cant director C/O SOCIETAL CDMO, INC., 1 E. UWCHLAN AVENUE, SUITE 112, EXTON PA 19341
Enloe J David Jr director, officer: Chief Executive Officer
James Charles Miller director 490 LAPP ROAD, MALVERN PA 19355
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Mathew Paul Arens director, 10 percent owner C/O FIRST LIGHT ASSET MANAGEMENT, LLC, 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
First Light Asset Management, Llc director, 10 percent owner 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
Laura L. Parks director C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN PA 29355
Michael Berelowitz director 415 EAST 37TH STREET, APT 36C, NEW YORK NY 10016
Ryan David Lake officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Scp Vitalife Partners (israel) Ii, L.p. 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355
Scp Vitalife Partners Ii Lp 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355